The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | Expediting radiotherapy in SCLC to reduce toxicity & improve outcomes
Oghenevwede Okuma, MBBS, The James Cook University Hospital, Middlesbrough, UK, comments the importance of expediting radiotherapy for limited-stage small cell lung cancer (SCLC), highlighting the benefits of concurrent treatment and adaptive radiotherapy in reducing toxicity to surrounding organs, such as the lungs, heart, and esophagus. Adaptive radiotherapy and innovative technologies, including artificial intelligence (AI), can help minimize toxicities while improving treatment plans. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think for limited-stage small cell, we want to get through the radiotherapy as quickly as possible. The concurrent treatment, as best case scenario, get concurrent treatment as quickly as possible. And then afterwards, start the adjuvant treatment, which we now have. Usually a few weeks afterwards, after the no evidence, you know, we want to then start the development as quickly as possible as well...
I think for limited-stage small cell, we want to get through the radiotherapy as quickly as possible. The concurrent treatment, as best case scenario, get concurrent treatment as quickly as possible. And then afterwards, start the adjuvant treatment, which we now have. Usually a few weeks afterwards, after the no evidence, you know, we want to then start the development as quickly as possible as well. Definitely, definitely with adaptive radiotherapy, we have better plans as well. And there are lots of AI coming into radiotherapy as well and looking for more innovative ways to deliver radiotherapy while reducing the toxicity to other organs. And also depending on the stage of the tumor and the structures we’re surrounding, key concerns for us is the mean lung dose, the heart dose, and the esophageal dose as well. And definitely adaptive radiotherapy will help to reduce some of these toxicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
